Neuroinflammation of Multiple Sclerosis studied G35
Conditions
Interventions
Group 1: To evaluate the added diagnostic value of the 7T MRSI (MR spectroscopic imaging) in comparison to established MRI methods, 3 patients groups suffering from Multiple Sclerosis (CIS, RRMS, SPMS
Sponsors
MR Exzellenzzentrum, Universitätsklinik für Radiodiagnostik, Medizinische Universität Wien
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 20 patients with first clinical relapse suggestive for MS (Multiple Sclerosis) 20 “active“ RRMS (Relapsing Remitting Multiple Sclerosis) patients with high clinical relapse rate (=2 relapses over last 2 years) or high numbers of active (Gadolinium-enhancing) lesions (>2 on MRI scan) 20 SPMS (Secondary Progressive Multiple Sclerosis) patients with EDSS (Expanded Disability Status Scale) =5.5 or 0.5 EDSS steps in patients with EDSS =6 in the absence of a relapse, a minimum EDSS score of 4 and pyramidal FS score of 2 and confirmed progression over =3 months
Exclusion criteria
Exclusion criteria: contraindications for MR imaging (claustrophobia, metal implants…), pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity of the developed MRSI (MR spectroscopic imaging) methods for the measurement of myo-inositol using a 7T MR tomograph as marker for neuroinflammation in comparison to conventional MRI. Sensitivity is determined at the end of the study using all collected patient and control data. | — |
Countries
Austria
Contacts
Public ContactWolfgang Bogner
MR Exzellenzzentrum, Universitätsklinik für Radiodiagnostik, Medizinische Universität Wien
Outcome results
None listed